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Rapport de synthèse 
Le diabète de type 2 est une maladie fréquente et en augmentation dans le monde entier. 
Malheureusement, elle est souvent diagnostiquée à un stade ou des complications sont déjà 
apparues. Depuis quelques années, des scores ont été développés pour identifier les sujets à risque 
de développer cette maladie. L'utilisation d'un tel score par le praticien pourrait amener ces patients 
à des mesures préventives, telles que le changement d'hygiène de vie, ou la prescription d'un 
traitement médicamenteux. Le but de notre étude est de comparer et de valider différents scores de 
risques de diabète de type 2 et de déterminer leur capacité à prédire la survenue de cette maladie 
dans la population de la cohorte CoLaus. 
Les premiers résultats, en étude transversale, ont tout d'abord montré de grandes différences quant 
à la population à risque d'un score à l'autre. En effet, le nombre de personnes à traiter varie 
considérablement selon la méthode utilisée. Ces différents scores ont donc nécessité une validation 
prospective. Ces résultats ont fait l'objet d'une publication (Schmid et col, Diabetes Care. 2011 
Aug;34(8):1863-8). 
Au moyen des données du suivi à 5 ans, il est sorti qu'un score de risque utilisant des variables 
biologiques et cliniques, ainsi qu'un score utilisant des variables uniquement cliniques, obtenaient de 
très bon résultats quant à la prédiction du diabète de type 2. En effet, un des scores testés donne 
une valeur prédictive positive d'environ 20% à 5 ans, ce qui signifie qu'un patient «détecté» sur 5 
pourrait bénéficier d'une intervention précoce. Toutefois, ces résultats concernent la population 
lausannoise et ne sont donc pas forcément applicables à l'ensemble de la population suisse. De plus, 
de plus amples études sont nécessaires évaluer l'efficacité d'un tel score dans la prévention du 
diabète en Suisse. Ces résultats ont fait l'objet d'une seconde publication (Schmid et col, Arch lntern 
Med. 2012 Jan 23;172(2):188-9). 
Dans un troisième volet de l'étude, l'impact de marqueurs génétiques a été évalué dans un sous-
groupe de la population CoLaus. Les résultats n'ont toutefois montré qu'une très faible amélioration 
de la prédiction du risque en utilisant ces marqueurs. Ceci devrait nous encourager à intensifier les 
efforts de prévention sur le style de vie pour toute la population, plutôt qu'une approche ciblée sur 
les personnes génétiquement prédisposées. Ces résultats ont fait l'objet d'une troisième publication 
(Schmid et col, J Clin Endocrinol Metab. 2012 Apr 24. [Epub ahead of print]). 
La même démarche méthodologique a été utilisée pour évaluer l'importance pronostique de 
plusieurs marqueurs inflammatoires (interleukines 1 et 6, TNF-, protéine C-réactive) hépatiques (GT) 
ou adipocytaires (leptine et adiponectine) dans la survenue du diabète. Ces résultats sont 
actuellement soumis au Journal of Clinicat Endocrino/ogy and Metabo/ism). 
Le contenu de ce travail a été présenté lors des congrès suivants: 
Société Suisse de médecine interne, Lausanne, 11-13 Mai 2011 (1 poster) 
Société Européenne de Cardiologie, Paris, 28 Août 2011 (3 posters) 
Société Suisse d'Endocrinologie et Métabolisme, Berne, 2 Décembre 2011 (2 posters) 
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Estimating the Risk of Developing 
Type 2 Diabetes: A Comparison of 
Several Risk Scores 
The Cohorte Lausannoise study 
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OBJECTIVE-Ta compare in the Swiss population the results of several scores estimating the 
risk of developing type 2 diabetes. 
RESIEARCH DESIGN AND METHODS-This was a single-center, cross-sectional study 
conducted between 2003 and 2006 in Lausanne, Switzerland. Overall, 3,251 women and 2,937 
men, aged 35-75 years, were assessed, of which 5,760 (93%) were free from diabetes and in-
cluded in the current study. The risk of developing type 2 diabetes was assessed using seven 
different risk scores, including clinical data with or without biological data. Participants were 
considered to be eligible for primary prevention according to the thresholds provided for each 
score. The results were then extrapolated to the Swiss population of the same sex and age. 
RESULTS-The risk of developing type 2 diabetes increased with age in all scores. The prev-
alence of participants at high risk ranged between 1.6 and 24.9% in men and between 1.1 and 
15.7% in women. Extrapolated to the Swiss population of similar age, the overall number of 
participants at risk, and thus susceptible to intervention, ranged between 46,708 and 636,841. In 
addition, scores that included the same clinical variables led to a significantly different prevalence 
of participants at risk (4.2% [95% Cl 3.4-5.0] vs. 12.8% [11.5-14.1] in men and 2.9% [2.4-3.6] 
vs. 6.0% [5.2-6.9] in women). 
CONCLUSIONS-The prevalence of participants at risk for developing type 2 diabetes varies 
considerably according to the scoring system used. To adequately prevent type 2 diabetes, risk-
scoring systems must be validated for each population considered. 
ype 2 diabetes is a serious disease 
with increasing prevalence. This dis-
ease remains asymptomatic for years, 
being discovered only at a stage with 
preexisting complications (1). Recent stud-
ies (2) have shown that lifestyle or medi-
cation intervention could prevent the 
incidence of type 2 dia be tes. Hence, screen-
ing tools are needed to identify participants 
with undiagnosed diabetes or those who 
are at risk for developing diabetes in 
the future. For this purpose, numerous 
risk scores recently have been proposed 
Diabetes Care 34:1863-1868, 2011 
(3-6). Participants at high risk of devel-
oping type 2 diabetes, according to the 
risk score threshold, are thus amenable 
to preventive measures. A good diabetes 
risk score ideally should be easily com-
pleted by the physician and rely on easily 
and routinely accessible clinical and bio-
logical parameters, such as age, family his-
tory, hypertension, anthropometry, or 
lifestyle habits. Moreover, the risk score 
has to be accurate enough to provide tar-
geted warnings for the patients. Sorne 
scores have been validated in selected 
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populations (3-7), prompting their use in 
other countries (8,9). Nevertheless, recent 
studies (10) have shown that risk scores 
that are developed in the same country 
can lead to different results. Likewise, one 
equation validated in one country might 
not provide adequate estimates in another; 
for instance, the Framingham cardiovascu-
lar risk equations can over- or underesti-
mate risk when directly applied to other 
populations (11). Finally, and to the best 
of our knowledge, no study has ever com-
pared the results of differing scoring sys-
tems in Switzerland. 
The current study aimed to compare 
the results of several scores that estimate 
the risk of developing type 2 diabetes 
using data from the Cohorte Lausannoise 
(CoLaus) study, a cross-sectional study 
conducted in Lausanne, Switzerland. The 
resulting number of subjects at risk for 
developing type 2 diabetes in Switzerland 
according to these different risk equations 
also was estimated. 
RESEARC:H DESIGN AND 
METHODS 
Risk scores 
We performed a PubMed search and 
selected risk scores for their relative nov-
elty and their applicability to the Swiss 
population. The score from the Swiss 
Diabetes Association, available on the 
Internet (8), also was assessed. This score 
actually is an adaptation of the Finnish 
Diabetes Risk Score (FINDRISC) score 
(7). Overall, seven risk scores, including 
clinical (C) or clinical and biological var-
iables (CB) were studied: 10-year risk 
scores from Kahn et al. (3) (C and CB); 
8-year risk score from Wilson et al. ( 4) 
(CB); 9-year risk score from Balkau et al. 
(6) (C); the prevalent undiagnosed diabe-
tes riskscore from Griffin et al. (5) (C); the 
risk score from the Swiss Diabetes Asso-
ciation (8); and the FINDRISC (C), which 
is a 5- to 10-year risk score (7). The char-
acteristics of the studies, where the scores 
were developed, and the variables in-
cluded in each score are summarized in 
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Supplementary Tables 1and2. From this 
point on, the scores will be referenced by 
the name of the first author, with a further 
differentiation by C or CB in the case of 
the Kahn and Balkau scores. 
We used the thresholds recommended 
by the authors to define participants at 
high risk of developing type 2 diabetes 
(Supplementary Table 1). These thresh-
olds were defined differently according 
to the study: Kahn (3), Wilson (4), and 
Balkau (6) used a probability, whereas the 
Swiss Diabetes Association and FINDRISC 
used a score above a given number of 
points. The initial publication from Griffin 
et al. (5) provided no threshold; hence, we 
used the 37% probability, which was used 
in another study (12). The scores from the 
Swiss DiabetesAssociation and FINDRISC 
included regular consumption of selected 
foods (fruits, vegetables, berries, and 
brown bread) and familial history of dia-
betes for second-degree parents (grand-
parents, cousins, and uncles). Because 
these data were not available in our study, 
the scoring system was adapted by reduc-
ing by one point the cutoff value for high-
risk participants. 
Recruitment 
The Co Laus study is a cross-sectional study 
in the Caucasian population of Lausanne, 
Switzerland, a town of 117,161 inhab-
itants, of which 79,420 are of a Swiss 
nationality. This study was approved by 
the institutional ethics committee of the 
University of Lausanne. The study was de-
signed to assess the prevalence and to 
identify the molecular determinants of 
cardiovascular risk factors. The population 
of Lausanne can be considered as repre-
sentative of the whole country because a 
considerable proportion is non-Swiss or 
cornes from other cantons (political re-
gions of Switzerland). In 2006, of 128,231 
Lausanne inhabitants, 38% were non-Swiss, 
30% came from other cantons (including 
Italian and German-speaking cantons), and 
only 32% were actually from the Vaud 
canton (13). 
The sampling procedure of the 
CoLaus study has been described previ-
ously (14). A complete list of Lausanne in-
habitants, aged 35-75 years (n = 56,694), 
was provided by the population registry of 
the city. A simple, nonstratified random 
sample of 35% of the overall population 
was drawn. The following inclusion criteria 
were applied: 1) provided written informed 
consent; 2) was aged 35-75 years; 3) was 
willing to take part in the examination 
and donate blood samples; and 4) was of 
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Caucasian origin, defined as having both 
parents and grandparents born in a re-
stricted list of countries (available from 
the authors). Recruitment began in June 
2003 and ended in May 2006. Participation 
rate was 41 %, and 6,188 Caucasian partic-
ipants (3,251 women and 2,937 men) took 
part in the study. 
All participants attended the outpa-
tient clinic of the University Hospital of 
Lausanne in the morning after an over-
night fast (minimum fasting time 8 h). 
Data were collected by trained field inter-
viewers in a single visit lasting -60 min. 
Clinical data 
The participants first received a question-
naire to record information about their 
lifestyle factors, namely tobacco use, al-
cohol use, and physical activity. According 
to their smoking histories, participants 
were classified as never, current, or former 
smokers. Current smokers were defined as 
giving a positive answer to the statement 
"I currently smoke," former smokers were 
defined as giving a positive answer to the 
statement "I don't smoke anymore," and 
never smokers were defined as giving a 
positive answer to the statement "I have 
never smoked." Alcohol consumption in-
cluded past and current drinking status as 
well as the number of alcoholic beverage 
units (wine, beer, and spirits) consumed 
over the week preceding the interview. A 
participant was considered to be physi-
cally active if he/she reported practicing 
at least 2 h ofleisure-time physical activity 
per week. 
During a second face-to-face meeting, 
the participants were asked if they or their 
first-degree family (i.e., parents, children) 
had presented with diabetes. The partic-
ipants also were asked if they had been 
diagnosed with hypertension or if they 
currently were being treated for hyper-
tension. Personal medicines, including 
prescription and self-prescribed drugs, 
were collected, together with their main 
indications. Only corticosteroids, being 
of systemic or topical use, were consid-
ered for testing the scores. Despite the fact 
that other medications, such as hydrochlo-
rothiazide or ACE inhibitors, have been 
shown to influence diabetes status (15), 
they were not included in the risk scores. 
Body weight and height were mea-
sured with participants standing without 
shoes in light indoor clothes. Body weight 
was measured in kilograms to the nearest 
100 g, using a Seca scale, which was 
calibrated regularly. Height was mea-
sured to the nearest 5 mm using a Seca 
height gauge. Waist was measured with a 
nonstretchable tape over the unclothed 
abdomen at the narrowest point between 
the lowest rib and the iliac crest. Two 
measures were made, and the mean (ex-
pressed in centimeters) was used for 
analyses. Blood pressure and resting pulse 
were measured three times using an 
Omron HEM-907 automated oscillomet-
ric sphygmomanometer on the left arm, 
with an appropriately sized cuff, after at 
least 10 min rest in the seated position. 
The average of the last two measurements 
was used for analyses. 
Biological analyses 
Fasting plasma glucose, HDL cholesterol, 
LDL cholesterol, triglycerides, and uric 
acid levels were measured by the Centre 
Hospitalier Universitaire Vaudois Clinical 
Laboratory using fresh blood samples 
within 2 h of blood collection. All meas-
urements were conducted in a Modular P 
apparatus (Roche Diagnostics, Basel, 
Switzerland). The following analytical pro-
cedures (with maximum interbatch and 
intrabatch coefficients of variation) were 
used: cholesterol by cholesterol oxidase-
peroxide + 4-aminophenazone + phenol 
(PAP) (1.6-1.7%); HDL cholesterol by 
cholesterol oxidase-PAP plus polyethylene-
glycol plus cyclodextrin (3.6--0.9%); glucose 
by glucose dehydrogenase (2.1-1.0%); 
triglycerides by glucose oxidase-P AP 
(2.9-1.5%); and uric acid by uricase-PAP 
(1.0-0.5%). 
Diabetes 
Diabetes was defined as fasting plasma 
glucose 2:7.0 mmol/L and/or the pres-
ence of oral hypoglycemic or insulin treat-
ment. Type 2 diabetes was defined in 
cases of diabetes without self-reported 
type 1 diabetes. Impaired fasting glucose 
was defined as fasting plasma glucose be-
tween 6.1 and 6.9 mmol/L without anti-
diabetes treatment. 
Statistical analysis 
Of the initial 6,188 partlClpants, 21 
(0.3%) had missing data for the vari-
ables of interest, 407 (6.6%) had diabetes, 
and 655 had impaired fasting glucose 
(10.6%). Diabetic participants were ex-
cluded, and the remaining 5,760 (93.l %) 
participants were used in the analyses. 
Characteristics of the patients included in 
our study are available in Supplementary 
Table 1. 
The prevalence of participants at risk 
for developing type 2 diabetes according to 
each score was determined and expressed 
care.diabetesjournals.org 
in percentages and 95% Cis. The number 
of participants at risk in Switzerland was 
then estimated for each score by applying 
the sex-specific and 10-year age-group-
specific prevalence obtained to the cor-
responding diabetes-free population 
numbers, obtained by averaging the pop-
ulation estimates between 2003 and 2006, 
provided by the Swiss Federal Statistical 
Office (www.statistique.admin.ch). To as-
sess the number of subjects without dia-
betes in the Swiss population, we assumed 
that the proportion of nondiabetic pa-
tients in our study was representative of 
the whole country. All statistical analyses 
were made using Stata version 11.1 (Stata, 
College Station, TX). 
RESULTS 
Prevalence of subjects at risk 
for type 2 diabetes 
The prevalence of participants at risk for 
developing type 2 diabetes is shown in 
Fig. 1. In men, the prevalence of partici-
pants at high risk of developing type 2 
diabetes was the following: 1.6% (1.2-
2.2) (Wilson); 4.2% (3.4-5.0) (Balkau); 
12.8% (11.5-14.1) (Kahn [C]); 13.5% 
(12.2-14.9) (Swiss Diabetes Association); 
13.7% (12.4-15.0) (Kahn [CB]); 22.9% 
(21.3-24.5) (FINDRISC); and 24.9% 
(23.4-26.6) (Griffin). In women, the cor-
responding values were 1.1 % (0.8-1.6) 
(Wilson); 2.9% (2.4-3.6) (Balkau); 6.0% 
(5.2-6.9) (Kahn [C]); 11.l % (10.0-12.3) 
(Swiss Diabetes Association); 6.1 % (5.3-
7 .0) (Kahn [CB]); 15.7% (14.5-17.1) 
(FINDRISC); and 10.7% (9.6-11.8) 
(Griffin). Overall, men tended to present 
a higher risk of type 2 diabetes than 
women. Extrapolated to the Swiss popula-
tion of the same age, the number of subjects 
at risk ranged from 46,708 to 636,841, 
more than a 13-fold variation (Table 1). 
Restricting the analysis to participants 
aged <65 years showed either slight in-
creases (Wilson) or decreases (FINDRISC; 
Griffin) in the prevalence of subjects at risk 
for developing type 2 diabetes (Supple-
mentary Table 4). Likewise, excluding 
from the analysis the 11 women with a pos-
sible pregnancy at examination did not 
change the results (data not shown). 
Comparison between scores 
We also checked whether the same par-
ticipants were considered to be at risk 
according to the different scores. For this, 
we compared the participants at risk for 
type 2 diabetes according to the scores 
that led to the lowest prevalence (Wilson 
and Balkau) and also according to the 
scores that included the same clinical 
variables (Balkau and Kahn [C]). The 
results are presented in Fig. 2. The scores 
classified a total of 612 participants as 
being at risk: n = 78, Wilson; n = 201, 
Balkau; and n = 558, Kahn (C). Of 78 
participants at risk according to Wilson 
et al. ( 4), only 21 (26.9%) also were con-
sidered at risk according to Balkau. 
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Figure !-Proportion of participants at high rish of developing type 2 diabetes according to each 
score, by sex. C and CB are only specified in the case of varions equations provided by the authors. 
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Likewise, of 201 participants at risk ac-
cording to Balkau, only 145 (72%) also 
were considered at risk according to 
Kahn (C). Only 19 patients were simulta-
neously classified as high-risk by ail three 
scores. 
CONCLUSIONS-To our knowledge, 
this is one of the few studies that assessed 
the effect of differing type 2 diabetes risk-
scoring systems in a given population. In 
agreement with previous studies (10,16), 
our results indicate that the prevalence of 
subjects at risk for developing type 2 di-
abetes varies considerably according to 
the scoring system used. This has a con-
siderable impact in the number of sub-
j ects susceptible of benefiting from 
measures regarding the primary preven-
tion of type 2 diabetes. 
The risk-scoring systems compared 
in this study shared several types of 
variables (Supplementary Table 1). For 
instance, all of them included a genetic 
background (personal or family history), 
which can be explained by the association 
between certain genes and diabetes (17), 
and most of them also included age, 
which has been shown to be related to 
the risk of diabetes. Most scores also in-
cluded obesity markers, such as BMI or 
waist circumference, as well as cardiovas-
cular risk factors, such as hypertension 
and dyslipidemia, all of which are in-
volved in the metabolic syndrome defini-
tion (18). Finally, some scores included 
lifestyle habits, whether protective, such 
as alcohol consumption and physical ac-
tivity, or deleterious, such as smoking, 
also in agreement with previous findings 
(19). It should be noticed that in some 
studies nondrinkers and former drinkers 
were included in the same group (3) and 
that the nonlinear, U-shaped association 
between alcohol consumption and the 
risk of developing type 2 diabetes (20) 
was not considered. Overall, these find-
ings suggest that any generic scoring sys-
tem that included clinical variables known 
to be related to type 2 diabetes (age, obe-
sity, cardiovascular risk factors, and life-
style) could be used to derive diabetes 
risk scores but that the relative weight of 
each variable might be different according 
to the population considered. For in-
stance, age, obesity, and the other factors 
mentioned vary by counny, and this may 
result in a differential importance to pre-
dict diabetes. Finally, the inclusion of 
other variables, such as biological and ge-
netic markers, also should be considered 
but is beyond the scope of our study (21). 
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Table 1-Number of participants in the Swiss population at high rish of developing type 2 diabetes according to each score, 
by sex and age-grnup 
Sex and Total Swiss Swiss Diabetes 
age-group population Wilson Balkau (C) Kahn (C) Association 
Men 
Age (years) 
35-44 620,900 4,964 12,046 36,924 18,462 
45-54 529,600 11,275 15,066 44,500 55,775 
55-64 441,700 9,281 24,394 84,151 77,181 
65-75 304,300 1,360 18,430 47,762 75,055 
Total 1,896,500 26,879 69,937 213,338 226,474 
Women 
Age (years) 
35-44 615,900 4,262 8,523 15,647 11,385 
45-54 522,500 5,133 11,434 20,022 37,148 
55-64 449,100 7,670 19,132 48,363 77,083 
65-75 361,700 2,765 13,166 20,802 72,050 
Total 1,949,200 19,829 52,256 104,834 197,666 
Total 3,845,700 46,708 122,192 318,172 424,140 
C and CB are only specified in the case of various equations provided by the authors. 
The two scoring systems that did not 
include age (i.e., Wilson and Balkau) gave 
the lowest prevalence rates of subjects 
at risk for type 2 diabetes, whereas the 
Griffin score, which includes a linear re-
lationship with age (5), provided the 
greatest prevalence. It is interesting to 
note that the scoring systems using age-
groups instead of age (3,8,9) provided in-
termediate prevalence rates. Considering 
how easy it is to collect age and the in-
creasing prevalence of type 2 diabetes 
with age (18), we can postulate that this 
variable should be included in any risk-
scoring system. Another possible ex-
planation for the low prevalence rates of 
participants at risk using the Wilson score 
is the fact that it includes a low HDL cho-
lesterol level, whose prevalence was 
36.9% in the original study. However, in 
the Colaus study (14), the prevalence of 
low HDL cholesterol was only 2.8%, 
which might lead to spurious results. 
Total N = 5760 
Figure 2-Nwnber of patients at high rish of 
developing type 2 diabetes according to three 
scores. 
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Overall, these findings further stress the 
importance of not only including certain 
variables but also their relative weighting 
and even the way they are coded to com-
pute the risk of developing type 2 dia-
betes. 
Only two scoring systems (Wilson 
and Kahn [CB]) included fasting glucose. 
This was somewhat unexpected because 
fasting glucose has a strong predictive 
value for diabetes (22). Indeed, in the 
study from Balkau et al. (6), fasting glu-
cose was considered to be the best predic-
tor, but no scoring system that included 
fasting glucose was provided, possibly be-
cause of the fact that the objective was to 
derive a clinically based scoring system. 
Most values for each variable included 
in the scoring systems were derived from 
logistic or Cox regression coefficients. 
Still, it should be noticed that some scor-
ing systems (i.e., Swiss Diabetes Associa-
tion) include variables (i.e., familial 
history) for which the scores were not 
based upon statistical analysis but on an 
"educated" proposal by the authors (7). 
As a subject might shift from a low-risk 
to a high-risk category by one single scor-
ing unit, care should be taken when such 
non-evidence-based scores are applied. 
Furthermore, the FINDRISC score has 
been used (and in some cases modified) 
by others (8,9) without any complemen-
tary statistical analysis or validation; there-
fore, the results obtained by these 
modified, nonvalidated scores might be 
questionable. Finally, many scoring sys-
tems did not take into account the non-
linear association between some variables 
Kahn (CB) Griffin FINDRISC 
34,745 35,471 29,116 
60,165 80,869 86,506 
85,325 145,119 146,256 
47,762 157,613 94,240 
227,998 419,072 356,118 
10,654 7,854 21,309 
23,427 25,714 55,443 
46,914 71,330 104,865 
25,641 88,014 99,106 
106,636 192,912 280,722 
334,634 611,984 636,841 
(i.e., alcohol consumption) and diabetes 
risk; the reason might be that introducing 
nonlinearity complicates the scoring sys-
tem, but no precise rationale could be ob-
tained from the literature. 
The prevalence rates of participants at 
risk for developing type 2 diabetes varied 
almost 13-fold according to the scoring 
system used, leading to considerable dif-
ferences in the number of subjects ame-
nable to prevention measures in the 
corresponding Swiss population. This 
great variability can be partly explained 
by the differences between the scoring 
systems. First, the variables used and their 
corresponding coefficients varied consid-
erably. Second, the thresholds used to 
define subjects at high risk also varied 
(30-46%), as shown in Table 1. Third, 
and as stated previously, the scoring sys-
tems were developed and validated in a 
given population, and applying them to a 
different population can lead to inconsis-
tent results, as it has been underlined in a 
previous Germanstudy (16). Overall, our 
results suggest that the indiscriminate use 
of a nonvalidated scoring system might 
lead to considerable differences in the 
number of subjects to prevent, with a 
likely under- or overuse of the limited 
available preventive resources. 
The agreement between the different 
scoring systems was disappointing. In-
deed, we initially expected that two scor-
ing systems detecting a low number of 
subjects at risk for diabetes would detect 
the same patients, but Fig. 2 shows that it 
is not the case. Likewise, even two scoring 
systems that included broadly the same 
care.diabetesjournals.org 
variables (i.e., Balkau and Kahn [ C]) failed 
to detect the same participants. Hence, 
our results indicate that different scoring 
systems detect different subjects at risk for 
developing type 2 diabetes and thus are not 
interchangeable. Adequate validation of 
these scoring systems using prospective 
data is therefore necessary to select the 
best system applicable to the population 
under study. The ongoing follow-up of 
the Co Laus cohort will allow this validation. 
Our study has several limitations. 
First, the predicting ability of the tested 
scores could not be achieved in the 
current study. Thus, it is unclear which 
of them will be the most accurate. The 
ongoing follow-up of the Colaus cohort 
will enable such a comparison. Second, 
the prevalence rates according to Swiss 
Diabetes Association and FINDRISC may 
be over- or underestimated as a result 
of our lack of dietary data and second-
degree familial history. Of interest, sensi-
tivity analyses showed that decreasing 
the threshold of these scores by two and 
three points led to a 50% increase in the 
number of subjects at risk for developing 
type 2 diabetes (Supplementary Table 6). 
These findings suggest that minor changes 
in the scoring system can lead to consider -
able changes in the number of subjects at 
risk for developing type 2 diabetes and that 
any risk-scoring system should be ade-
quately validated before being applied 
in a given population. Third, although the 
participation rate was similar to other epi-
demiological studies (23), it was rather low 
( 4 1 % ) , which might limit the generaliza-
tion of findings. Indeed, the CoI.aus study 
may not be representative of the Swiss pop-
ulation, but seeing the great variability in 
the number ofhigh-risk patients, this mis-
take may not be of great relevance. In ad-
dition, there was no sex or ZIP code 
distribution difference between the source 
population, the random sample, and the 
Colaus participants. On the other hand, 
the Colaus sample had more women and 
was slightly younger than the correspond-
ing Swiss population aged 35-75 years 
(Supplementary Table 7). Hence, it can be 
argued that although the Colaus sample is 
not fully representative of the Swiss popu-
lation, the differences in population struc-
ture are relatively small. Likewise, our 
population was at relatively low risk for di-
abetes, and it is unknown how this might 
influence the performance of some of the 
risk scores if applied in other populations 
or ethnie groups. Still, most equations we 
used have been developed in European 
countries and should thus be generalizable 
care.diabetesjournals.org 
to the European population. On the other 
hand, it has been shown that risk scores 
developed in the same country lead to dif-
ferent results (10). Thus and again, a pre-
cise validation within a given of any risk 
score should be conducted before its appli-
cation in clinical or public health practice. 
Fourth, diabetic subjects were excluded on 
the basis of fasting but not on 2-h plasma 
glucose; hence, diabetic subjects by 2-h 
glucose (but not by fasting glucose) were 
retained in the analysis. Nevertheless, be-
cause the number of subjects with type 2 
diabetes (by 2-h glucose) is fixed, our re-
sults still indicate that the number of sub-
jects at risk for developing type 2 diabetes 
varies considerably according to the risk 
score used. Finally, this article only in-
cluded leisure-time physical activity, and 
occupational physical activity was not con-
sidered. Hence, it is possible that the risk of 
developing type 2 diabetes might be over -
estimated when using the equations that 
include physical activity. 
In summary, our results indicate that 
the prevalence of participants at risk for 
developing type 2 diabetes varies consid-
erably according to the scoring system 
used. To adequately prevent type 2 di-
abetes, risk-scoring systems should be 
validated for each population considered. 
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Validation of 'T Type 2 Diabetes Mellitus 
Risk Scores in a Population-Based Cohort: 
CoLaus Study 
0 ne of the challenges for public health in the com-ing years is the expected increase of type 2 dia-betes mellitus (T2DM) prevalence and its re-
sulting health burden and costs. 1·2 For the physician, 
although recommendations regarding who to screen for 
T2DM are available, the application of a validated risk 
score would enable a better targeting of high-risk sub-
jects and th us an impravement of preventive measures. 
Indeed, numeraus risk scores for T2DM have been de-
veloped, but few studies have compared them in popu-
lations different from those they have been derived from. 
It is also unclear whether all risk scores have the same 
prognostic validity. 
The aim of this study was to assess the validity of vari-
ous T2DM risk scores in predicting the incidence ofT2DM 
in a Swiss population-based cohort. 
Methods. Seven T2DM risk scores were selected in the 
present study. Four were based on clinical data: the 10-
year risk score from Kahn et aP (Kahn clinical); the 9-year 
risk score from Balkau et al4 ; the prevalent undiagnosed 
diabetes risk score from Griffin et al5; the Finnish Type 
2 Diabetes Risk Score (FINDRISC), which has been de-
veloped in 2 cohorts followed for 5 and 10 years6 ; and 
finally the risk score from the Swiss Diabetes Associa-
tion, available online,7 which is actually adapted from 
FINDRISC. The 2 remaining risk scores were based on 
the association of clinical and biological data: the 10-
year risk score from Kahn et aP (Kahn clinical +biologie) 
and the 8-year risk score from Wilson et al. 8 We used the 
thresholds pravided by the authors, and each score had 
its area under the receiver operating characteristic curve 
(AROC), sensitivity, specificity, and negative and posi-
tive predictive values assessed. We tested these scores in 
3060 nondiabetic participants from Lausanne, Switzer-
land (44.6% men; mean [SD] age, 52.6 [10.6] years), fol-
lowed up for 5 years (study period, 2003-2011).9 Inci-
dent dia be tes was defined as fasting plasma glucose level 
greater than or equal to 126.13 mg/dL (to couvert to mil-
limoles per liter, multiply by 0.0555) and/or presence of 
oral hypoglycemic or insulin treatment. 
Results. A total of 169 patients (5.5%) developed T2DM 
during follow-up. Compared with participants who did 
not develop T2DM, they were more frequently male 
(69.8% vs 43.l %); were older (mean [SD] age, 57.1 [9.4] 
vs 52.3 [10.6] years); had a higher frequency of family 
historyofT2DM (31.4% vs 19.3%) (allP< .001); and had 
a higher resting heart rate (69 [10] vs 67 [9] beats/min 
[P < .05]). They practiced less leisure-time physical ac-
tivity ( 45.6% vs 60.3%); had higher body mass index (29.0 
[3.9] vs 25.l [4.0] [calculated as weight in kilograms di-
vided by height in meters squared]), waist circumfer-
ence (100.3 [10.9] vs 86.8 [12.2] cm), and fasting plasma 
glucose (110.45 [9.37] vs 95.32 [9.37] mg/dL), triglyc-
eride (189.38 [184.07] vs 111.50 [79.65] mg/dL [to cou-
vert to millimoles per liter, multiply by 0.0113]), and uric 
acid (6.03 [1.32] vs 5.11 [1.35] mg/dL [to couvert to mi-
cramoles per liter, multiply by 59.485]) levels; and had 
lower high-density lipoprotein cholesteral levels (53.28 
[13.51] vs 64.09 [16.60]mg/dL [to couvert to milli-
moles per liter, multiply by 0.0259]) (all P< .001). The 
performance of the 7 T2DM risk scores is given in the 
Table. Most risk scores had a high AROC, specificity, 
and negative predictive value, white their sensitivity and 
positive predictive values were low. 
Comment. Most variables included in the risk scores were 
significantly different between participants who devel-
oped T2DM and those who did not, which confirms their 
prognostic role. The best results were obtained by the 
Kahn clinical +biologie risk score. However, a risk score 
based on simple clinical data (FINDRISC) also had a high 
AROC, which could be more convenient regarding health 
costs and acceptability by patients. Indeed, using data from 
our hospital, applying the Kahn clinical +biologie risk 
score would lead to an extra cost of US$ 12.02 per screened 
patient relative to the FINDRISC score. 
Our study has several limitations. Follow-up time was 
limited to 5 years; still, our findings are in agreement with 
the performances reported in the original studies, sug-
gesting that our results should also be reliable after a 10-
year follow-up. Sorne factors such as fruit consumption 
and second-degree familial history could not be as-
sessed in this study owing to lack of information; al-
though we corrected for such missing data, it is possible 
that the performance of the corresponding risk scores 
might have been reduced. Still, one of these risk scores 
(FINDRISC) ranked second best in our study, suggest-
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Table. Performances of the Tested Scores 
AROC K Sensitivity, % Specificily, % PPV NPV 
Risk Score (95%CI) (95%CI) {95%CI) (95%CI) {95%CI) (95%CI) 
Balkau et al,4 c 76.3 (73.1-79.5) 0.095 (0.038-0.152) 10.1 (6.0-15.6) 97.4 (96.8-98.0) 18.5 (11.1-27.9) 94.9 (94.0-95.6) 
Kahn et al,3 C 79.2 (76.0-82.3) 0.209 (0.152-0.266) 32.5 (25.5-40.2) 93.2 (92.2-94.1) 21.8 (16.9-27.4) 95.9 (95.1-96.6) 
Griffin et al,5 C 79.9 (76.9-82.9) 0.199 (0.154-0.243) 50.9 (43.1-58.6) 86.3 (85.0-87.5) 17.8 (14.5-21.6) 96.8 (96.0-97.4) 
Wilson et al,8 CB 83.0 (79.9-86.1) 0.123 (0.059-0.186) 8.9 (5.1-14.2) 99.1 (98.6-99.4) 35.7 (21.6-52.0) 94.9 (94.1-95.7) 
Swiss Diabetes 84.7 (82.2-87.2) 0.253 (0.201-0.305) 49.7 (41.9-57.5) 90.0 (88.9-91.1) 22.5 (18.4-27.1) 96.8 (96.1-97.5) 
Association,7 c 
FINDRISC,6 C 85.1 (82.7-87.6) 0.251 (0.207-0.294) 65.7 (58.0-72.8) 85.2 (83.8-86.5) 20.6 (17.3-24.3) 97.7 (97.0-98.2) 
Kahn et al,3 CB 89.9 (87.9-91.9) 0.339 (0.278-0.399) 49.1 (41.4-56.9) 93.7 (92.8-94.6) 31.4 (25.9-37.4) 96.9 (96.2-97.5) 
Abbreviations: AROC, area under the receiver operating characteristic curve; C, clinical; CB, clinical +biologie; FINDRISC, Finnish Type 2 Diabetes Risk Score; 
NPV, negative predictive value; PPV, positive predictive value. 
ing that the reduction in its predictive power may not 
be significant. In this study, physical activity was de-
fined as at least 2 h/wk of leisure-time physical activity, 
but it was defined as 4 h/wk or 30-min/d in the original 
publications.6·7 Finally, this study was limited to white 
participants and whether the results also apply to other 
ethnicities is unknown. 
In conclusion, this is the first study, to our knowl-
edge, to compare the prognostic validity of several risk 
scores for T2DM. The Kahn clinical +biologie risk score 
has the highest AROC, but the clinical FINDRISC score 
may be more practical and less expensive for screening. 
Further research is needed to assess the real impact of 
these scores in preventing T2DM. 
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Frequent Fracture of TraplEase lnferior 
Vena Cava Filters: A Long·lerm 
Follow-up Assessment 
P ulmonary thromboembolism (PTE) is one of the most significant complications of deep vein throm-bosis (DVT) of the lower extremities. To pre-
vent PTE, an inferior vena cava filter (IVCF) is often used.1 
The TrapEase IVCF (Cordis Endovascular, Johnson&:. 
Johnson) is one of the most popular permanent IVCFs 
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Current Genetie Data Do Not lmprove the Prediction 
of Type 2 Diabetes Mellitus: The Colaus Study 
Rémy Schmid, Peter Vollenweider, François Bastardot, Julien Vaucher, 
Gérard Waeber, and Pedro Marques-Vidal 
lnstitute of Social and Preventive Medicine (R.S., P.M.-V.), University Hospital of Lausanne, CH-1010 
Lausanne, Switzerland; Department of Medicine (P.V., F.B., J.V., G.W.), Internai Medicine, University 
Hospital of Lausanne Faculty of Biology and Medicine, CH-1011 Lausanne, Switzerland 
Context: Severa! genetic risk scores ta identify asymptomatic subjects at high risk of developing 
type 2 diabetes mellitus (T2DM) have been proposed, but it is unclear whether they add extra 
information to risk scores based on clinical and biological data. 
Objective: The objective of the study was to assess the extra clinical value of genetic risk scores in 
predicting the occurrence of T2DM. 
Design: This was a prospective study, with a mean follow-up time of 5 yr. 
Setting and Subjects: The study included 2824 nondiabetic participants (1548 women, 52 ± 10 yr). 
Main Outcome Measure: Six genetic risk scores for T2DM were tested. Four were derived from the 
literature and two were created combining ail (n = 24) or shared (n = 9) single-nucleotide polymorphisms 
of the previous scores. A previously validated clinic + biological risk score for T2DM was used as reference. 
Results: Two hundred seven participants (7.3%) developed T2DM during follow-up. On bivariate 
analysis, no differences were found for ail but one geneticscore between nondiabetic and diabetic 
participants. After adjusting for the validated clinic + biological risk score, none of the genetic 
scores improved discrimination, as assessed by changes in the area under the receiver-operating 
characteristic curve (range -0.4 to -0.1 %), sensitivity (-2.9 to -1.0%), specificity (0.0-0.1 %), and 
positive (-6.6 to +0.7%) and negative (-0.2 to 0.0%) predictive values. Similarly, no improvement 
in T2DM risk prediction was found: net reclassification index ranging from -5.3 to -1.6% and 
nonsignificant (P 2': 0.49) integrated discrimination improvement. 
Conclusions: ln thisstudy, adding genetic information to a previouslyvalidated clinic + biological score 
does not seem to improve the prediction of T2DM. (J Clin Endocrinol Metab 97: EOOOO-EOOOO, 2012) 
Prevalence of type 2 diabetes mellitus (T2DM) is in-creasing worldwide, and the identification of sub-
jects at high risk of developing T2DM is needed (1). For 
this purpose, several T2DM risk scores have been devel-
oped; most include clinical and biological variables, but 
genetic scores have also been proposed (2-4). Whether 
these genetic scores improve the prediction of T2DM is 
still a matter of debate. Hence, we aimed to assess the 
improvement in predicting T2DM brought by genetic 
scores to a validated clinical and biological risk score. 
Materials and Methods 
A subsample of the Cohorte Lausannoise (CoLaus) study includ-
ing 2824 participants (1548 women, aged 52 :': 10 yr) free from 
diabetes and with available 5-yr follow-up data (overall study 
period 2003-2010) was analyzed. The CoLaus Study is a cross-
sectional study aimed at assessing the prevalence and identifying 
the molecular determinants of cardiovascular risk factors in the 
Caucasian population of Lausanne, Switzerland. Caucasian or-
igin was defined as having both parents and grandparents born 
in a restricted list of countries (available from the authors). The 
methodology of the CoLaus Study has been described previously 
ISSN Print 0021-972X ISSN Online 1945-7197 
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Abbreviations: Cl, Confidence interval; Co Laus, Cohorte Lausannoise study; IDI, integrated 
discrimination improvement; NRI, netreclassification improvement; SNP, single·nucleotide 
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(5). The study was approved by the Ethics Committee of the 
Vaud Canton, and ail subjects provided their written informed 
consent before be included in the study. Nuclear DNA was ex-
tracted from whole blood, and genotyping was performed using 
the Affymetrix 500 K single-nucleotide polymorphism (SNP) 
chip (Affymetrix, Santa Clara, CA). Genotypes were called using 
BRLMM (6), and a set of unmeasured SNP was imputed using 
IMPUTE version 0.2.0 (7) and CEU haplotypes from HapMap 
release 21. For imputation, only autosomal SNP present in Hap-
Map release 21 were used; the data set used for imputation was 
5,435 unrelated CoLaus individuals and 390,631 measured 
SNP. Four genetic risk scores for T2DM were computed as in-
dicated (2-4). The score proposed by Meigs et al. (4) was com-
puted without the INS gene because no valid imputed data were 
available. The scores by Lin et al. (2) were derived from the 
cross-sectional, baseline data of the CoLaus Study. The un-
weighted score was a linear combination of the SNP. Because the 
amplitude of the effect varies somewhat between diabetes sus-
ceptibility genes, in an attempt to penalize the SNP with a less 
reliable odds ratio estimate, a weighted score was also used by 
weighting each SNP using the log of the lower boundary of the 
reported 95% confidence interval (CI). Two other genetic scores 
were created: one combining al! SNP of the previous scores and 
another combining the SNP shared by the scores. The list of SNP 
used is provided in the Supplemental Table 1, published on The 
Endocrine Society's Journals Online web site at http://jcem. 
endojournals.org. Incidental diabetes was defined as fasting 
plasma glucose level 7.0 mmol/liter or greater and/or the pres-
ence of oral hypoglycemic or insulin treatment. 
Statistical analysis was conducted using Stata version 11.2 
(Stata Corp LP, College Station, TX). The added predictive value 
for T2DM of each of these six genetic scores was assessed by 
logistic regression adjusting for a validated T2DM risk score ( 8). 
The score uses the following data to estimate the risk of devel-
oping T2DM: age, family history of T2DM, Black race (not used 
in this study), alcohol drinking, height, waistcircumference, rest-
ing heart rate, hypertension ( defined as a systolic blood pres-
sure 2"': 140 mm Hg and/or a diastolic blood pressure 2"':90 mm Hg 
or presence of antihypertensive drug treatment), fasting blood 
glucose, high-density lipoprotein cholesterol, triglycerides, and 
uric acid. A participant was considered as being at risk if his/her 
probability of presenting with T2DM was greater than 46% (9). 
Each genetic score was tested after adjusting for the continuons 
values of the risk of developing T2DM as assessed by the clinical 
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and biological score (range 0-81 % ). The discrimination perfor-
mances of each mode! including one genetic score were assessed 
using the area under the receiver-operating characteristic curve 
and corresponding 95% CI. The sensitivity, specificity, positive 
and negative predictive values, and corresponding 95% CI were 
also calculated using the exact binomial method. Calibration 
was visually checked by comparing the predicted probabilities 
with the observed incident cases of T2DM in each decile of pre-
diction after including the genetic score (10). The improvement 
of T2DM prediction by including genetic scores was assessed by 
calculating the net reclassification improvement (NRI) and the 
integrated discrimination improvement (!DI). The 95% CI for 
the NRI was computed using normal approximation. 
Results 
Of the 2824 participants, 207 (7.3 % ) developed T2DM after 
5 yr. Significant differences were found between participants 
who developed T2DM and those who did not for most pa-
rameters of the clinical risk score (Supplemental Table 2). On 
bivariate analysis, no differences were found for all but one 
genetic scores studied between nondiabetic and diabetic par-
ticipants: Lin et al. (2) unweighted: 14.5 ± 2.4 vs. 15 .0 ± 2.4 
(mean ± SD), respectively, P < 0.01; Lin et al. weighted: 
1.42 ± 0.27 vs. 1.45 ± 0.28, P = 0.08; Meigs et al. (24): 
16.6 ± 2.5 vs. 16.9 ± 2.4, P = 0.11; Lyssenko et al. (3): 
10.6 ± 2.1vs.10.8 ± 2.1, P = 0.31; shared SNP: 9.9 ± 1.7 
vs. 10.1±1.7, P = 0.11; and all SNP: 22.4 ± 3.4 vs. 22.9 ± 
3.4, P = 0.08. Multivariate analysis by logistic regression 
adjusting for a validated clinical + biological T2DM risk 
score showed no significant improvement (and even in some 
cases a worsening) in all discrimination parameters and in 
risk prediction for all genetic scores studied (Tables 1and2). 
Discussion 
Our findings suggest that adding genetic information to a 
validated score based on clinical and biological variables 
TABLE 1. Impact of adding different genetic scores in the predictive capacity of a clinical + biological risk score for 
T2DM, using a 46% probability threshold to define high-risk subjects 
Positive predictive Negative predictive 
Risk score AROC Sensitivity Specificity value value NRI IDI (x103) 
Kahn et al. (clinical + biological) 86.3 (83.5; 88.3) 11.1(7.2;16.2) 98.7 (98.1; 99.1) 39.7 (27.0; 53.4) 93.3 (92.4; 94.2) 
risk score (9) 
+ Lin et al. (unweighted) (2) 86.2 (83.8; 88.5) 9.2 (5.6; 14.0) 98.7 (98.2; 99.1) 35.8 (23.1; 50.2) 93.2 (92.2; 94.1) -3.52 (-8.48; 1.43) 1.57 (0.52) 
+Lin etal. 86.0 (83.6; 88.4) 8.2 (4.9; 12.8) 98.7 (98.2; 99.1) 33.3 (20.8; 47.9) 93.1 (92.1; 94.1) -5.31 (-9.60; -1.02) 0.28 (0.51) 
(weighted) (2) 
+ Meigs et al. (4) 86.1 (83.7; 88.5) 8.7(5.2; 13.4) 98.8 (98.3; 99.2) 36.7 (23.4; 51.7) 93.2 (92.2; 94. 1) -4.26 (-8.90; 0.37) 0.09 (0.50) 
+ Lyssenko et al. (3) 85.9 (83.5; 88.3) 9.7 (6.0; 14.5) 98.7 (98.2; 99.1) 37.7 (24.8; 52.1) 93.3 (92.3; 94.2) -2.58 (-5.61; 0.46) -0.14 (0.49) 
+ Shared SNP by Lin et al., 86.1 (83.7; 88.4) 10.1(5.0;15.1) 98.8 (98.3; 99.2) 40.4 (27.0; 54.9) 93.3 (92.3; 94.2) -1.59 (-5.88; 2.71) 1.78 (0.52) 
Meigs et al., and Lyssenko et al. 
+ Ali SNP used by Lin et al., 86.1 (83.7; 88.5) 8.2 (4.9; 12.8) 98.8 (98.3; 99.2) 34.7 (21.7; 49.6) 93.2 (92.1; 94.1) -5.21 (-9.50; -0.91) -0.10 (0.50) 
Meigs et al., and Lyssenko et al. 
Statistical analysis by logistic regression. Values are expressed as percentage and 95% Cl or as value X 103 and P value (for IDI). AROC, Area under 
the receiver operating curve. 
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TABLE 2. Impact of adding different genetic scores in the predictive capacity of a clinical + biological risk score for 
T2DM, using a 30% probability threshold to define high risk subjects 
Positive predictive Negative predictive 
Risk score AROC Sensitivity Specificity value value NRI 
Kahn et al. (clinical + biological) 85.9 (83.4; 88.3) 30.0 (23.8; 36.7) 96.1 (95.3; 96.8) 38.0 (30.6; 46.0) 94.6 (93.6; 95.4) 
risk score (9) 
+ Lin et al. (unweighted) (2) 86.2 (83.8; 98.5) 30.0 (23.8; 36.7) 96.1 (95.3; 96.8) 37.8 (30.4; 45.7) 94.5 (93.6; 95.4) -0.05 (-5.61; 5.51) 
+ Lin et al. (weighted) (2) 86.0 (83.6; 88.4) 30.4 (24.2; 37.2) 95.9 (95.0; 96.6) 36.8 (29.6; 44.5) 94.6 (93.6; 95.4) 0.54 (-2.51; 3.60) 
+ Meigs et al. (4) 86.1 (83.7; 88.5) 29.5 (23.4; 36.2) 96.0 (95.2; 96. 7) 37.0 (29.6; 44.8) 94.5 (93.6; 95.3) -1.04 (-5.69; 3.61) 
+ Lyssenko et al. (3) 85.9 (83.5; 88.3) 30.0 (23.8; 36.7) 96.1 (95.3; 96.8) 37.8 (30.4; 45.7) 94.5 (93.6; 95.4) -0.05 (-5.61; 5.51) 
+ Shared SNP by Lin et al., Meigs et al., 86.1 (83. 7; 88.4) 29.0 (22.9; 35.7) 95.8 (95.0; 96.6) 35.5 (28.3; 43.2) 94.5 (93.5; 95.3) -2.19 (-7.74; 3.37) 
and Lyssenko et al. 
+ Ali SNP used by Lin et al., Meigs et al., 86.1 (83.7; 88.4) 30.0 (23.8; 36. 7) 96.0 (95.2; 96.7) 37.1 (29.8; 44.9) 94.5 (93.6; 95.4) -0.20 (-4.51; 4.11) 
and Lyssenko et al. 
Statistical analysis by logistic regression. Values are expressed as percentage and 95% Cl. AROC, Area under the receiver operating curve. 
brings no extra benefit in predicting T2D M incidence over 
a 5-yr follow-up, a finding in agreementwith other studies 
(2-4, 11, 12). These findings applied not only to ail four 
genetic scores published, including one developed using 
the original baseline population (2), butalso to other com-
binations of SNP related to diabetes. A possible explana-
tion might rely on the fact that the clinical + biological 
score included family history of diabetes, which implicitly 
includes some genetic information. Finally, the fact that 
the genetic score developed using the original baseline data 
added no information to the prediction of T2DM empha-
sizes the importance of prospective studies in evaluating 
genetic markers for disease prediction ( 13). The fact that 
the unweighted score of Lin et al. (2) had a high degree of 
significance but added no information on the prediction of 
T2DM also shows that high statistical significance is not 
necessarily associated with clinical utility. 
Our study has some limitations, It was not possible to 
impute the INS gene to compute the score of Meigs et al. 
( 4). It is th us likely that the predictive capacity of the score 
is underestimated, but the magnitude of this possible bias 
could not be estimated. Because the predictive ability of 
the genetic scores increases with follow-up (3 ), itwill be of 
interest to verify whether our findings hold true with a 
longer follow-up time. Indeed, the 46% threshold of the 
clinical + biological risk score was initially determined for 
a 10-yr follow-up period (9), which might be too high and 
explain the low sensitivity levels; nevertheless, reducing 
this threshold to 30% increased sensitivity but did not 
change the results for the genetic scores (Table 2), Still, 
given the little extra information provided by ail genetic 
scores, their interest in general clinical practice appears to 
be rather modest. Furthermore, such genetic counseling 
requires specific equipment, which is expensive and could 
thus lead to a debatable commercial use (14). The genetic 
risk scores are based on additive effects only, and in future 
studies, the importance of nonlinear effects of genetic vari-
ants should be taken into account. The CoLaus Study re-
cruited only subjects aged aider than 35 yr, and it is likely 
that the genetic scores might be more interesting for pre-
dicting patients who will develop T2DM at a younger age 
and who also may not have clinical characteristics such as 
obesity. Finally, a beneficial effect of physical activity 
among genetically predisposed patients has been recently 
shown (15), which allows us to prefer a lifestyle modifi-
cation approach for the whole population, regardless of 
genetic susceptibility (16) and a targeted intervention to 
the more at-risk individuals as assessed by clinical and 
biological data. 
In summary, our study shows that adding genetic in-
formation does not seem to improve discrimination and 
risk prediction of T2DM compared with a score based on 
common, easily assessable clinical + biological variables. 
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